1. Bristol-Myers Squibb’s profitability: can eliquis do the job in 2017? Market realist report;Patrick,2017
2. Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY);Connolly;N Engl J Med,2009
3. National Institute of Health and Care Excellence. Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) (updated 2018) available from: https://www.nice.org.uk/advice/ktt16.
4. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (ROCKET AF);Patel;N Engl J Med,2011
5. Apixaban versus warfarin in patients with atrial fibrillation (ARISTOTLE);Granger;N Engl J Med,2011